- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Vimida
Population: General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- People at high risk of STIs
- Outpatient clinic
- Non-hospital health centre
- STD/STI clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Hospital
- Outpatient clinic
- Monkeypox virus
- General population
- Adolescents (12-17 years)
- Non-hospital health centre
- Telemedicine
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- VAC∆6
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Hydroxy gas
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Monoclonal antibodies
- Temelimab